|Articles|April 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Partnerships: Bargaining Biotechs

Author(s)Kevin Gopal

Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.

Articles in this issue

almost 25 years ago

Internet DTC - Minding Your P's & Q's

almost 25 years ago

Regulation: Two-Track Plan

almost 25 years ago

Policy: Tectonic Shift

almost 25 years ago

Liberated?

almost 25 years ago

A Matter of Taste

almost 25 years ago

Pediatric Mandate

almost 25 years ago

Genentech's Passion for Patients

almost 25 years ago

Regulation: OK After All

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content